SignatureFD’s Outlook Therapeutics OTLK Stock Holding History

SignatureFD’s Portfolio OTLK Stock Details OTLK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-3	Closed	-$14	–	3230
2023 Q3	$14	Hold	3	–	–	﹤0.01%	3178
2023 Q2	$113	Buy	+3	New	+$82	﹤0.01%	3172

Other funds holding OTLK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Scotia Capital Toronto, Ontario, Canada $24.3B AUM 29.21% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SignatureFD's OTLK Position: Q4 2023 in Review

SignatureFD sold out of Outlook Therapeutics (OTLK) in Q4 2023, closing a stake of 3 shares — an estimated $14 sold.

SignatureFD first reported a position in OTLK in Q2 2023 and held it in 2 quarters. The position peaked at $113 in Q2 2023. 87 funds tracked by Wall St. Rank hold OTLK as of Q4 2023.

SignatureFD reported no remaining Outlook Therapeutics position as of Q4 2023 after selling out during the quarter.
SignatureFD sold 3 Outlook Therapeutics shares in Q4 2023, an estimated $14.
SignatureFD first reported a position in Outlook Therapeutics in Q2 2023 and held it in 2 quarters.
SignatureFD's Outlook Therapeutics position peaked at $113 in Q2 2023.
87 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q4 2023.

Based on SignatureFD's 13F filing for Q4 2023, filed 1 Feb 2024.